Loading stocks --
Market News
English اردو

Liven Pharma Cuts Quarterly Net Loss by 76% to Rs7.37m

LIVEN Liven Pharma Limited
Rs. 52.40 +9.99%
Stock ImpactPositive

Liven Pharma Limited (PSX: LIVEN) reported a 75.56% year-on-year reduction in its net loss to Rs7.37 million for the quarter ended September 30, 2026, compared to a net loss of Rs30.16 million recorded in the same period last year.

The company's basic and diluted loss per share (LPS) improved to Rs0.07 from a restated Rs0.28 in the corresponding quarter of the previous year. The narrower loss was primarily driven by an 81.66% reduction in other expenses, lower administrative and selling expenses, a surge in other income to Rs7.60 million (from Rs4,032), and a higher taxation credit of Rs2.71 million.

However, operational profitability faced pressure as sales cost expanded by 244.93% to Rs16.87 million, pushing the company into a gross loss of Rs2.57 million despite a 62.04% increase in total revenue.

DescriptionQ1 2026 (PKR)Q1 2025 (PKR)Change (%)
Sales14,293,3558,820,81062.04%
Cost of Sales(16,865,196)(4,889,428)244.93%
Gross Profit / (Loss)(2,571,841)3,931,382N/A
Administrative Expenses(7,060,596)(9,555,737)-26.11%
Selling & Distribution Expenses(3,476,898)(4,765,879)-27.05%
Other Expenses(3,799,999)(20,720,838)-81.66%
Other Income7,600,2944,032N/A
Net Loss(7,371,540)(30,157,472)-75.56%
LPS (PKR)(0.07)(0.28)-75.00%

Read the full story on the original publisher’s website.

Open original article